Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment

Cancer

Volumn 116, Issue 20, 2010, Pages 4849-4856

  Winget, Marcy ^a,b   Hossain, Shakhawat ^a   Yasui, Yutaka ^a   Scarfe, Andrew ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

Colorectal cancer; Disparities; Health services research; Therapy; Treatment guidelines

Indexed keywords

AGE; AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; COLON ADENOCARCINOMA; COMORBIDITY; CONSULTATION; DEMOGRAPHY; ELECTRONIC MEDICAL RECORD; FEMALE; GEOGRAPHY; HOSPITAL DISCHARGE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIOECONOMICS; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; COLON TUMOR; PATHOLOGY; RISK FACTOR;

ADENOCARCINOMA; AGED; ALBERTA; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; RESIDENCE CHARACTERISTICS; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 78349255362     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25250     Document Type: Article

References (27)

1. [No authors listed] NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358. (Pubitemid 20042739)
3. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294:2703-2711. (Pubitemid 41770099)
4. Hershman DL, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107:2581-2588. (Pubitemid 44845611)
5. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850-857. (Pubitemid 32590779)
6. Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20:1192-1202. (Pubitemid 34177424)
7. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293-1300. (Pubitemid 46606406)
8. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population based study. Cancer J. 2001;7:213-218.
9. Cree M, Tonita J, Turner D, et al. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clin Colorectal Cancer. 2009;8:141-145.
10. Tucker TC, Howe HL, Weir HK. Certification for population-based cancer registries. J Registry Manage. 1999;26:24-27.
11. Fritz A, Percy C, Jack A, et al. eds. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
12. Greene FL, Page DL, Fleming ID, et al. eds. Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
13. Danielson B, Winget M, Gao Z, et al. Palliative radiotherapy for women with breast cancer. Clin Oncol (R Coll Radiol). 2008;20:506-512.
14. Canadian Institute for Health Information. Reducing Gaps in Health: A Focus on Socio-Economic Status in Urban Canada. Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2008.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
16. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining co-morbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139. (Pubitemid 41587600)
17. Alberta Cancer Board, Alberta Provincial Gastrointestinal Tumour Team. Early Stage Colon Cancer: Clinical Practice Guideline. Report No. GI-004. Edmonton, Alberta, Canada: Alberta Cancer Board; 2008.
18. Winget M, Turner D, Tonita J, et al. Across-province standardization and comparative analysis of time-to-care intervals for cancer [serial online]. BMC Cancer. 2007;7:186.
19. Deddens JA, Peterson MR. Approaches for estimating prevalence ratios. Occup Environ Med. 2008;65:501-506. (Pubitemid 351969703)
20. Greenberg ER, Chute CG, Stukel T, et al. Social and economic factors in the choice of lung cancer treatment. N Engl J Med. 1988;318:612-617.
21. Campbell NC, Elliott AM, Sharp L, et al. Impact of deprivation and rural residence on treatment of colorectal and lung cancer. Br J Cancer. 2002;87:585-590.
22. Luo R, Giordano SH, Freeman JL, et al. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006;11:1025-1033. (Pubitemid 44564812)
23. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
24. Extermann M, Overcash J, Lyman GH, et al. Co-morbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587. (Pubitemid 28175784)
25. Kutner JS, Vu KO, Prindvlle SA, et al. Patient age and cancer treatment decisions: patient and physician views. Cancer Pract. 2000;8:114-119. (Pubitemid 30233046)
26. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993;85:1580-1584. (Pubitemid 23304686)
27. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86:1766-1770. (Pubitemid 24373451)